88 related articles for article (PubMed ID: 18501510)
1. Genetic deletion of Fatty Acid Amide Hydrolase results in improved long-term outcome in chronic autoimmune encephalitis.
Webb M; Luo L; Ma JY; Tham CS
Neurosci Lett; 2008 Jul; 439(1):106-10. PubMed ID: 18501510
[TBL] [Abstract][Full Text] [Related]
2. Neuropathic pain behaviours in a chronic-relapsing model of experimental autoimmune encephalomyelitis (EAE).
Olechowski CJ; Truong JJ; Kerr BJ
Pain; 2009 Jan; 141(1-2):156-64. PubMed ID: 19084337
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis.
Li FQ; Sempowski GD; McKenna SE; Laskowitz DT; Colton CA; Vitek MP
J Pharmacol Exp Ther; 2006 Sep; 318(3):956-65. PubMed ID: 16740622
[TBL] [Abstract][Full Text] [Related]
4. Deficient p75 low-affinity neurotrophin receptor expression does alter the composition of cellular infiltrate in experimental autoimmune encephalomyelitis in C57BL/6 mice.
Küst B; Mantingh-Otter I; Boddeke E; Copray S
J Neuroimmunol; 2006 May; 174(1-2):92-100. PubMed ID: 16519950
[TBL] [Abstract][Full Text] [Related]
5. PPARgamma antagonists exacerbate neural antigen-specific Th1 response and experimental allergic encephalomyelitis.
Raikwar HP; Muthian G; Rajasingh J; Johnson C; Bright JJ
J Neuroimmunol; 2005 Oct; 167(1-2):99-107. PubMed ID: 16091293
[TBL] [Abstract][Full Text] [Related]
6. Deficient p75 low-affinity neurotrophin receptor expression exacerbates experimental allergic encephalomyelitis in C57/BL6 mice.
Copray S; Küst B; Emmer B; Lin MY; Liem R; Amor S; de Vries H; Floris S; Boddeke E
J Neuroimmunol; 2004 Mar; 148(1-2):41-53. PubMed ID: 14975585
[TBL] [Abstract][Full Text] [Related]
7. The influence of uric acid treatments on liver glutathione system prevent oxidative damages in experimental autoimmune encephalomyelitis mice.
Allameh A; Maleklou N; Zargari M; Sanati MH
Neurosci Lett; 2008 Jul; 439(1):111-5. PubMed ID: 18501514
[TBL] [Abstract][Full Text] [Related]
8. PSGL-1 is not required for development of experimental autoimmune encephalomyelitis.
Osmers I; Bullard DC; Barnum SR
J Neuroimmunol; 2005 Sep; 166(1-2):193-6. PubMed ID: 16005524
[TBL] [Abstract][Full Text] [Related]
9. IL-21 receptor expression determines the temporal phases of experimental autoimmune encephalomyelitis.
Liu R; Bai Y; Vollmer TL; Bai XF; Jee Y; Tang YY; Campagnolo DI; Collins M; Young DA; La Cava A; Shi FD
Exp Neurol; 2008 May; 211(1):14-24. PubMed ID: 18353312
[TBL] [Abstract][Full Text] [Related]
10. Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis.
Gresle MM; Shaw G; Jarrott B; Alexandrou EN; Friedhuber A; Kilpatrick TJ; Butzkueven H
J Neurosci Res; 2008 Dec; 86(16):3548-55. PubMed ID: 18709652
[TBL] [Abstract][Full Text] [Related]
11. Behavioral and pathological outcomes in MOG 35-55 experimental autoimmune encephalomyelitis.
Jones MV; Nguyen TT; Deboy CA; Griffin JW; Whartenby KA; Kerr DA; Calabresi PA
J Neuroimmunol; 2008 Aug; 199(1-2):83-93. PubMed ID: 18582952
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of CNTF in Mesenchymal Stem Cells reduces demyelination and induces clinical recovery in experimental autoimmune encephalomyelitis mice.
Lu Z; Hu X; Zhu C; Wang D; Zheng X; Liu Q
J Neuroimmunol; 2009 Jan; 206(1-2):58-69. PubMed ID: 19081144
[TBL] [Abstract][Full Text] [Related]
13. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine.
Black JA; Liu S; Carrithers M; Carrithers LM; Waxman SG
Ann Neurol; 2007 Jul; 62(1):21-33. PubMed ID: 17654737
[TBL] [Abstract][Full Text] [Related]
14. The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice.
Aizman E; Mor A; Chapman J; Assaf Y; Kloog Y
J Neuroimmunol; 2010 Dec; 229(1-2):192-203. PubMed ID: 20869125
[TBL] [Abstract][Full Text] [Related]
15. VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.
Roscoe WA; Welsh ME; Carter DE; Karlik SJ
J Neuroimmunol; 2009 Apr; 209(1-2):6-15. PubMed ID: 19233483
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide and TNFalpha effects in experimental autoimmune encephalomyelitis demyelination.
Farias AS; de la Hoz C; Castro FR; Oliveira EC; Ribeiro dos Reis JR; Silva JS; Langone F; Santos LM
Neuroimmunomodulation; 2007; 14(1):32-8. PubMed ID: 17700038
[TBL] [Abstract][Full Text] [Related]
17. Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model.
Belmar NA; Lombardo JR; Chao DT; Li O; Ma X; Pong-Afar M; Law DA; Starling GC
J Neuroimmunol; 2009 Jul; 212(1-2):65-73. PubMed ID: 19477024
[TBL] [Abstract][Full Text] [Related]
18. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
19. CCR6 regulates EAE pathogenesis by controlling regulatory CD4+ T-cell recruitment to target tissues.
Villares R; Cadenas V; Lozano M; Almonacid L; Zaballos A; Martínez-A C; Varona R
Eur J Immunol; 2009 Jun; 39(6):1671-81. PubMed ID: 19499521
[TBL] [Abstract][Full Text] [Related]
20. Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model.
Jung EJ; Hur M; Kim YL; Lee GH; Kim J; Kim I; Lee M; Han HK; Kim MS; Hwang S; Kim S; Woo AM; Yoon Y; Park HJ; Won J
J Pharmacol Exp Ther; 2009 Dec; 331(3):1005-13. PubMed ID: 19741152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
